A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
University of Pittsburgh
Genentech, Inc.
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC
Washington University School of Medicine
Washington University School of Medicine
Sutro Biopharma, Inc.
Neonc Technologies, Inc.
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Essen Biotech
University of California, San Diego
Prelude Therapeutics
Memorial Sloan Kettering Cancer Center
Takeda
Novartis
Merck Sharp & Dohme LLC
VM Oncology, LLC
Merck Sharp & Dohme LLC
Leap Therapeutics, Inc.
NuCana plc
Medicenna Therapeutics, Inc.
OncoC4, Inc.